Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Under Cornerstone’s Ownership, Zyflo Asthma Med Repositioned For Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

After completing a reverse merger with Critical Therapeutics last year, Cornerstone has retooled the marketing message for the asthma medication and ramped up commercial support.

You may also be interested in...



Cornerstone Buys EKR Therapeutics To Expand Hospital Growth Strategy

Cornerstone gains two commercial products for the acute-care hospital setting, Cardene and Retavase, with the acquisition of EKR Therapeutics for $125 million upfront and potential milestones.

Critical Therapeutics, Cornerstone BioPharma To Merge

Critical had been in line for delisting from NASDAQ; new firm, Cornerstone Therapeutics, will apply to relist.

Sage's Regulatory Strategy For Zuranolone Remains Uncertain

The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.

Topics

UsernamePublicRestriction

Register

PS069309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel